Niagen Bioscience has launched a pre-filled, ready-to-inject liquid form of nicotinamide riboside, dispensed through a clinician-directed telehealth platform and a licensed compounding pharmacy from 22 October. The subcutaneous route bypasses digestion, but the company has published no clinical data on the injectable format and makes no claim of superiority over oral NR. The launch signals the migration of NAD+ precursors from the supplement shelf into prescription-adjacent channels.
Key Points
- Pre-filled NR vial removes mixing and reconstitution steps at home
- No clinical data published comparing injected NR to oral
- Compounded, not FDA-approved; quality depends on dispensing pharmacy
Longevity Analysis
NAD+ availability underpins cellular energy generation and repair capacity, which is why precursor supplementation has become a fixture of longevity practice despite uncertainty about how much circulating NR actually reaches tissue. Subcutaneous delivery sidesteps first-pass metabolism and gut conversion, a plausible rationale that remains untested here — the pharmacokinetic case has not been made public. The more consequential development may be structural: physician oversight, intake screening and pharmacy dispensing introduce accountability that direct-to-consumer supplements lack, while compounded preparation shifts quality assurance onto a single pharmacy rather than a regulated manufacturing standard.
Original published by Longevity.Technology, by Kyle Umipig.